Table 2. Impact of α-arrestin deletion on the abundance of PM proteins affected by the CHX treatment.

Fold-change ratios of the abundance of PM proteins identified in Table 1 between the CHX-treated artΔ and WT strains. The first two columns indicate the UniProtKB accession number and name of proteins. The remaining columns correspond to artΔ+CHX/WT ctrl ratio, specifying the protein relative abundance in the CHX-treated arrestin-knockout strains divided by its relative abundance in the CHX-treated WT. The same total amount of proteins was analyzed in all conditions tested. The red and blue colors specify whether the ratio is significantly higher or lower than 1 after hypothesis testing (i.e., with a p-value < 0.05), respectively. A protein displaying a red ratio (artΔ+CHX/WT+CHX > 1) is more abundant in the artΔ+CHX than in the WT+CHX condition. We interpret an increase in surface protein upon α-arrestin deletion (i.e., indicated in red) as reflecting a defect in internalization of that PM protein. Inversely, a protein with a blue ratio (artΔ+CHX/WT+CHX < 1) is less abundant in the artΔ+CHX than in the WT+CHX. White ratios are not significantly different from one upon hypothesis testing, regardless of their absolute values. Proteins are classified as in Table 1. Displayed ratios correspond to the geometric means from 3 independent experiments.

Accession	Name	art1Δ+CHX/WT+CHX	art2Δ+CHX/WT+CHX	art3Δ+CHX/WT+CHX	art4Δ+CHX/WT+CHX	art5Δ+CHX/WT+CHX	art6Δ+CHX/WT+CHX	art7Δ+CHX/WT+CHX	art8Δ+CHX/WT+CHX	art9Δ+CHX/WT+CHX	art10Δ+CHX/WT+CHX	bul1Δ+CHX/WT+CHX	bul2Δ+CHX/WT+CHX
P32901	PTR2	9.0	10.8	10.8	6.2	11.2	8.6	2.6	4.4	2.6	2.3	17.7	2.4
Q05998	THI7	1.2	4.1	1.0	0.6	0.8	0.4	0.3	0.3	11.3	0.3	0.5	0.3
P38631	FKS1	5.2	3.0	5.5	2.5	3.2	2.1	1.7	1.4	3.5	1.8	2.9	1.0
P04817	CAN1	3.5	2.0	1.4	1.4	1.2	1.4	1.5	1.7	6.5	1.2	1.2	1.8
Q01896	ENA2	1.7	2.4	6.8	4.7	1.5	1.1	1.5	1.4	1.7	1.4	0.5	1.1
P32791	FRE1	5.4	4.2	4.7	3.1	3.6	2.4	2.5	1.9	2.8	1.9	2.8	1.7
P32466	HXT3	3.0	1.5	2.1	8.4	1.3	0.7	1.7	0.8	3.6	1.2	1.5	0.7
P38085	TAT1	2.4	1.8	2.2	1.1	1.6	1.6	1.4	1.4	0.7	1.2	1.2	1.6
Q06689	INA1	1.2	0.9	1.6	0.8	0.8	0.4	0.8	0.4	0.5	0.7	0.1	0.3
P32465	HXT1	4.6	2.8	4.4	9.3	2.6	1.6	2.2	1.8	1.7	2.4	1.4	1.9
P39004	HXT7	0.6	0.4	0.3	1.1	0.6	0.2	0.9	0.6	0.1	0.7	0.1	0.4
P32467	HXT4	0.7	0.6	0.6	2.8	0.5	0.6	0.7	0.5	0.4	0.6	0.2	0.5
P38079	YRO2	3.9	1.2	2.8	1.2	1.5	0.6	2.0	1.1	0.4	1.5	1.7	0.5
P40088	FTR1	2.2	1.0	1.8	1.6	1.7	0.8	1.3	0.6	2.1	1.1	1.2	0.5
P05030	PMA1	4.8	0.7	2.9	1.6	2.2	0.5	1.3	0.4	0.4	0.8	0.6	0.3
Q12256	TPO4	3.2	1.5	2.1	2.1	1.8	1.4	1.6	1.0	0.2	1.1	0.8	1.0
P38993	FET3	2.8	0.8	1.4	1.7	1.8	1.1	1.2	0.6	2.1	0.9	1.1	0.7
P49573	CTR1	1.2	1.3	2.0	1.5	1.3	1.1	1.4	0.9	0.4	1.1	1.1	0.8
P40474	QDR2	0.7	0.7	1.0	0.7	0.6	0.4	1.0	0.7	1.2	0.9	0.3	0.4
P22146	GAS1	1.7	1.2	2.0	1.0	1.1	0.3	1.4	0.7	0.2	1.1	0.7	0.3
P33302	PDR5	0.8	2.4	4.7	2.9	2.4	1.1	3.0	1.4	2.1	2.2	0.5	1.4
P32568	SNQ2	1.9	1.5	2.6	1.3	1.3	0.8	2.4	1.1	2.6	1.5	1.4	0.7
P53049	YOR1	2.3	1.5	1.8	1.5	1.7	0.8	1.5	1.1	1.4	1.1	1.1	0.7
P23292	YCK2	1.4	0.8	1.3	1.2	1.1	0.7	1.1	0.8	0.9	0.9	0.8	0.7
P48231	TCB2	0.4	0.8	0.7	0.8	0.5	0.5	0.7	0.7	1.1	0.8	0.7	0.5
P01120	RAS2	1.1	0.8	1.3	1.0	1.1	0.7	1.0	0.6	0.1	0.9	0.7	0.5
Q12466	TCB1	0.4	0.4	0.5	0.7	0.5	0.3	0.7	0.6	0.6	0.7	0.4	0.3
Q00245	RHO3	1.0	0.9	1.0	1.0	1.0	0.5	0.9	0.7	1.1	0.7	0.4	0.5
Q03640	TCB3	0.4	0.5	0.7	0.7	0.5	0.3	0.6	0.5	0.8	0.6	0.4	0.3
P38250	IST2	0.5	0.4	0.6	0.8	0.6	0.5	0.6	0.5	1.1	0.9	0.6	0.3
Q12207	NCE102	0.8	0.5	0.8	0.4	0.6	0.4	0.8	0.7	0.3	0.8	0.5	0.4
P06780	RHO1	0.7	0.6	0.8	0.6	0.8	0.5	0.8	0.7	0.5	0.7	0.8	0.4
Q08245	ZEO1	0.6	0.9	1.3	0.4	0.9	0.4	1.1	0.9	0.2	0.9	0.5	0.4

Abbreviations: CHX, cycloheximide; PM, plasma membrane; WT, wild-type